Craft
  • Home
  •  / Kyowa Kirin
Kyowa Kirin

Kyowa Kirin

Revenue

¥352.2 B

FY, 2021

Market Capitalization

$12.3 B

2022-09-19

Kyowa Kirin Summary

Company summary

Overview
Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system. It specializes in therapeutic antibodies, small molecule drugs, therapeutic nucleic acids, and regenerative medicine. The company was formed as a result of a merger between Kyowa Hakko and Kirin Pharma.
Type
Public
Founded
2008
HQ
Tokyo, JP | view all locations
Website
https://www.kyowakirin.com
Cybersecurity rating
Sectors

Key people

  • Shintaro Hasegawa

    Shintaro Hasegawa, President and Chief Executive Officer

    • Noriya Yokota

      Noriya Yokota, Director of the Board

      • Yutaka Osawa

        Yutaka Osawa, Representative Director Executive Vice President

        • Akira Morita

          Akira Morita, Director of the Board

          LocationsView all

          31 locations detected

          • Tokyo, Tokyo HQ

            Japan

            Otemachi Financial City Grand Cube, 1-9-2 Otemachi

          • Bedminster, NJ

            United States

            135 Route 202/206, Suite 6

          • Princeton, NJ

            United States

            212 Carnegie Center Dr Suite 400

          • San Diego, CA

            United States

            9420 Athena Cir, La Jolla

          • Sydney, NSW

            Australia

            68 York St

          • Shanghai, Shang Hai Shi

            China

            970 Longdong Road,Pilot Free Trade Zone

          and 25 others

          Kyowa Kirin Financials

          Summary financials

          Revenue (FY, 2021)
          ¥352.2B
          Gross profit (FY, 2021)
          ¥274.7B
          Net income (FY, 2021)
          ¥52.3B
          Cash (FY, 2021)
          ¥335.1B
          EBIT (FY, 2021)
          ¥60.0B
          Enterprise value
          ($322.8B)

          Footer menu